AstraZeneca announced today that the US Department of Justice has ended its investigation into alleged misconduct associated with the pivotal PLATO trial. The company said it had fully cooperated with the investigation, which began in October of 2013. … Click here to read the full post on Forbes. …
UK Politician Urges More Use Of Ticagrelor To Preserve AstraZeneca Jobs In UK
January 14, 2013 by 3 Comments
Use it or lose it. A UK politician is urging the National Health Service (NHS) to increase use of the antiplatelet drug ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) in order to prevent the loss of British jobs. Like nearly all the major pharmaceutical companies, AstraZeneca has been fighting…
FDA Approves Generic Clopidogrels As Plavix Loses Patent Protection
May 17, 2012 by 1 Comment
For the second time in the past six months, a cardiology mainstay drug has lost patent protection and gone generic. Today the FDA announced that it had approved several generic versions of clopidogrel (Plavix), the antiplatelet drug that for many years was the second best-selling drug in the world. Last November the best-selling drug of all time, Lipitor…
The Medicines Company Collaborates with AstraZeneca To Sell Brilinta (ticagrelor)
April 25, 2012 by Leave a Comment
The Medicines Company will collaborate with AstraZeneca to help sell Brilinta (ticagrelor), AstraZeneca’s struggling oral antiplatelet drug. The collaboration is the first stage of “a global collaboration for acute ischemic heart disease compound” announced by the two companies today. AstraZeneca will pay $15 million per year for The Medicines Company’s Brilinta-related sales activities, scheduled to begin in May….
Recent Comments